Disease Burden of Prostate Cancer from 2014 to 2019: Estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey.

Abstract

Abstract Purpose To evaluate the disease burden of prostate cancer (PC), and assess key influencing factors associated with the disease expenditures of PC in the US. Methods The total deaths, incidence, prevalence, Disability-Adjusted Life Years of prostate cancer were obtained from the Global Burden of Disease Study 2019. The Medical Expenditure Panel Survey was used to estimate the healthcare expenditures and productivity loss, and to investigate the payment and utilization pattern of healthcare resources in the US. A multivariable logistic regression model was conducted on medical expenditure to assess key influencing factors for the expenditures. Results For patients aged 49 and above, the burden in all age groups maintain a modest increase trend over the six-year period. The estimated annual medical expenditure ranged from $24.8 to $39.2 billion from 2014 to 2019. The patients’ productivity loss is approximately $1,200 per patient per year. The top three major components of medical costs were hospital inpatient stays, prescription medicines, and office-based visits. Medicare represented the largest source of payment for survivors. In term of drug consumptions, genitourinary tract agents (57.0%) and antineoplastics (18.6%) are the primary treatment drugs for these patients. High medical expenditures were positively associated with age (p = 0.005), having private health insurance (p = 0.016), more comorbidities, currently no smoke (p = 0.001), and patients’ self-perceived in fair/poor health status (p < 0.001). Conclusions From 2014 to 2019, the national real-world data of PC revealed that the disease burden in the US kept increasing, which were partly associated with patient characteristics.